Keywords: karo, bio, 2nd-qtr, losses, down, sweden-based, reported
Karo Bio 2nd-qtr losses down by 7%
Article | 22 July 2002
Sweden-based Karo Bio reported an operating loss of 86.5 million Swedishkronor ($9.4 million) for the third quarter of 2002, a decrease of 7.4% on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
